- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02175433
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
The dose escalation study will have two parts:
- Dose Escalation of AGS67E without myeloid growth factor (GF)
- Dose Escalation of AGS67E with myeloid growth factor (GF)
Subjects will be enrolled sequentially into dose cohorts starting with AGS67E without GF.
All subjects will receive a single 30 minute intravenous (IV) infusion of AGS67E once every three weeks. Subjects will continue treatment until disease progression, intolerability of AGS67E, investigator decision or consent withdrawal.
This dose escalation will first determine the maximum tolerated dose (MTD) of AGS67E without GF and then determine the MTD of AGS67E with GF. Once an MTD has been established, the study may enroll subjects into respective expansion cohorts of 12 subjects each at doses recommended by the data review team (DRT) (expansion cohort without GF and/or expansion cohort with GF).
During dose escalation, the Data Review Team will review cumulative unaudited data on an interim basis to review subject safety, recommend exploring additional doses and/or schedules, or the expansion of existing cohorts.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- Site CA0005
-
-
-
-
California
-
Duarte, California, Yhdysvallat, 91010
- Site US0006
-
Stanford, California, Yhdysvallat, 94305
- Site US0002
-
-
Kansas
-
Fairway, Kansas, Yhdysvallat, 66205
- Site US0004
-
-
New York
-
New York, New York, Yhdysvallat, 10019
- Site US0001
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Refractory or relapsed chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) or non-Hodgkin lymphoma (NHL) (including those of T cell origin)
- Eastern Cooperative Oncology Group performance score (ECOG) ≤ 2
- Negative pregnancy test (women of childbearing potential)
Hematologic function, as follows (no platelet transfusion within 2 weeks and no RBC transfusion within 4 days before the first dose of study drug)
- Absolute neutrophil count (ANC) ≥ 1,000/μL
- Platelets ≥ 75,000/μL
- Hemoglobin ≥ 8 g/dL (may be transfused ≥ 5 days)
- Renal function: serum creatinine ≤ 2.0 mg/dL and estimated creatinine clearance of ≥ 45 mL/min by the Cockcroft-Gault equation
- Direct bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Serum albumin ≥ 2.5 g/dL
- Aspartate aminotransferase (AST) ≤ 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
- Alanine aminotransferase (ALT) ≤ 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
- Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least 6 weeks after termination of study therapy
Exclusion Criteria:
- Preexisting sensory and/or motor neuropathy Grade ≥ 2
- Small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within 2 weeks before first dose of study drug
- Radioimmunotherapy within 4 weeks before first dose of study drug
- Use of any investigational drug (including marketed drugs not approved for this indication) within 14 days prior to the first dose of study drug
- Any P-gp inducers/inhibitors or strong CYP3A inhibitors within 2 weeks before the first dose of study drug (See Appendix F for list of excluded drugs)
- Anti Graft-Versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drug
- Platelet transfusion within 2 weeks and RBC transfusion within 4 days before the first dose of study drug
- Known central nervous system (CNS) disease
History of other primary malignancy (including myeloid malignancy, e.g., myelodysplastic syndrome), unless
- Curatively resected nonmelanomatous skin cancer
- Other malignancy curatively treated with no known active disease present and no systemic treatment administered for 3 years before the first dose of study drug
- Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of the first dose of study drug, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication
- Women who are pregnant or lactating
- Known HIV positive or AIDS
- Positive Hepatitis B surface antigen test
- Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
Known sensitivity to any of the components of the investigational product AGS67E:
- AGS67E
- L-Histidine
- α-trehalose dihydrate or
- polysorbate 20
- History of thromboembolic events (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) ≤ 2 weeks before the first dose of study drug and/or clinical diffuse intravascular coagulation (DIC)
- Active infection requiring treatment ≤7 days before the first dose of study drug
- Condition or situation which may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study
- Any medical, psychiatric, addictive or other disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Dose Escalation of AGS67E 0.05 mg/kg Without GF
Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 0.1 mg/kg Without GF
Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 0.3 mg/kg Without GF
Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 0.6 mg/kg Without GF
Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 0.9 mg/kg Without GF
Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 1.2 mg/kg Without GF
Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Expansion of AGS67E 0.9 mg/kg Without GF
Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 1.2 mg/kg With GF
Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 1.5 mg/kg With GF
Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Escalation of AGS67E 1.8 mg/kg With GF
Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Kokeellinen: Dose Expansion of AGS67E 1.5 mg/kg With GF
Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
|
intravenous (IV) infusion
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
---|---|
Incidence and nature of adverse events
Aikaikkuna: up to 34 months
|
up to 34 months
|
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Pharmacokinetic parameter for Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-21)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)
Aikaikkuna: Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Escalation: Days 1-4, 8, 15, 22, 43-46, 50, 64 for Cycles 1-4 and predose once every 3 weeks in subsequent cycles. Expansion: Days 1, 3, 8, 22, 43, 45, 64 in Cycles 1-4 and predose once every 3 weeks in subsequent Cycles up to an average of 4 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Incidence of Anti-Drug Antibody (ADA) formation to the fully human monoclonal antibody (AGS67C) and antibody-drug conjugate (AGS67E)
Aikaikkuna: Up to 34 months
|
Up to 34 months
|
|
Incidence of tumor response
Aikaikkuna: Up to 34 months
|
Tumor response is defined as either a complete response (CR) or partial response (PR)
|
Up to 34 months
|
Objective response rate (ORR)
Aikaikkuna: Up to 34 months
|
ORR for a cohort is defined as the percentage of subjects who experience a best response of either complete response (CR) or partial response (PR) in that cohort.
|
Up to 34 months
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Opintojohtaja: Associate Medical Director, Astellas Pharma Global Development, Inc.
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- AGS67E-14-1
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
IPD-jaon aikakehys
IPD-jaon käyttöoikeuskriteerit
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- CSR
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Relapsed Lymphoid Malignancy
-
International Extranodal Lymphoma Study Group (IELSG)Aktiivinen, ei rekrytointiMucosa Associated Lymphoid Tissue (MALT) -lymfoomaEspanja, Italia, Itävalta
-
Grupo Español de Linfomas y Transplante Autólogo...Valmis
Kliiniset tutkimukset AGS67E
-
Astellas Pharma Global Development, Inc.LopetettuAkuutti myelooinen leukemiaYhdysvallat, Kanada